DPFS Devolved Portfolio (Pilot)
Lead Research Organisation:
University of Nottingham
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
This is an award of a devolved portfolio under a pilot phase, as part of the implementation of the Development Pathway Funding Scheme (DPFS). DPFS Devolved Portfolios are block awards for specific universities to support goal-orientated translational research projects. The award allows universities to allocate the money to different translational projects more responsively based on their relative progress. For example the university might decide to stop a particular project and recycle the money allocated to it into other proposals. All projects supported by the Portfolio fall within the remit of the Development Pathway Funding Scheme (DPFS).
People |
ORCID iD |
Publications
Glenn JR
(2014)
'VASPFix' for measurement of VASP phosphorylation in platelets and for monitoring effects of P2Y12 antagonists.
in Thrombosis and haemostasis
McLaren J
(2014)
A biodegradable antibiotic-impregnated scaffold to prevent osteomyelitis in a contaminated in vivo bone defect model
in European Cells and Materials
Ahmed MA
(2012)
A CD44?/CD24? phenotype is a poor prognostic marker in early invasive breast cancer.
in Breast cancer research and treatment
Urbanowicz RA
(2015)
A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.
in Journal of virology
Ward C
(2010)
A green light for improved resuscitation.
in Midwives
Soria D
(2010)
A methodology to identify consensus classes from clustering algorithms applied to immunohistochemical data from breast cancer patients.
in Computers in biology and medicine
Soria D
(2013)
A quantifier-based fuzzy classification system for breast cancer patients.
in Artificial intelligence in medicine
Iyú D
(2011)
Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist.
in Arteriosclerosis, thrombosis, and vascular biology
Rahman C
(2013)
Adjuvant Chemotherapy for Brain Tumors Delivered via a Novel Intra-Cavity Moldable Polymer Matrix
in PLoS ONE
| Description | Breast Cancer Prognostic |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Impact | Evaluation of Gene expression profiling and expanded immunohistochemistry tests to guide selection of chemotherapy regimes in breast cancer management. |
| Description | Early Stage IP |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Impact | Meetings with UK IPO to illustrate challenges and importance of patent applications in commercialisation of early stage medical devices. |
| Description | InnovateUK/MRC Biomedical Catalyst |
| Amount | £1,400,000 (GBP) |
| Funding ID | HeartLight: Heart-Rate Monitoring for Neonatal Resuscitation |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2015 |
| End | 08/2017 |
| Description | Prof Brigitte Scammell: Innovate UK Award with Locate Therapeutics |
| Amount | £1,392,904 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Prof Brigitte Scammell: Wellcome Trust VIP Award |
| Amount | £17,770 (GBP) |
| Organisation | Wellcome Trust |
| Department | Wellcome Trust Bloomsbury Centre |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Prof David Brook: Wellcome Trust Seeding Drug Discovery |
| Amount | £3,120,000 (GBP) |
| Funding ID | 107562/Z/15/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Prof David Walker: Brain Tumour UK |
| Amount | £750,000 (GBP) |
| Organisation | The Brain Tumour Charity |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Prof Jonathan Ball: FP7 |
| Amount | € 5,990,000 (EUR) |
| Organisation | European Commission |
| Department | Seventh Framework Programme (FP7) |
| Sector | Public |
| Country | European Union (EU) |
| Start | |
| Description | Professor Barrie Hayes Gill - University of Nottingham Hermes |
| Amount | £23,500 (GBP) |
| Organisation | University of Nottingham |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | SurePulse - University of Nottingham IAA |
| Amount | £59,840 (GBP) |
| Organisation | University of Nottingham |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | UoN MRC CiC award to PI Sharkey and Hayes-Gill Round 8; Newborn resuscitation monitoring device |
| Amount | £97,817 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2019 |
| End | 03/2020 |
| Title | DM Cell Lines |
| Description | the group has established a series of cell lines from more than 20 DM patients. Four of these have been stably transfected with a telomerase-expressing plasmid to allow continued growth in culture. Two of the lines have also been infected with an inducible plasmid to express MyoD, which promotes differentiation into myoblasts and myotubes. |
| Type Of Material | Cell line |
| Year Produced | 2010 |
| Provided To Others? | Yes |
| Impact | Identification of hit compounds for treatment of myotonic dystrophy |
| Title | NPI |
| Description | Use of fuzzy logic to define new patient classifications for breast cancer |
| Type Of Material | Data analysis technique |
| Provided To Others? | No |
| Impact | Greater clarification of breast cancer classes allowing for clearer diagnosis, treatment and prognosis. |
| Description | Bone Scaffolds |
| Organisation | Biomet, Inc |
| Department | Biomet UK |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The R&D team have supplied formulations of bone scaffold polymer to Biomet to test in a number of orthopaedic applications. |
| Collaborator Contribution | Design and manufacture of unique bone scaffold polymers. |
| Impact | Anticipated licensing agreement. |
| Start Year | 2011 |
| Description | EU7 Platelets |
| Organisation | European Commission |
| Department | Seventh Framework Programme (FP7) |
| Country | European Union (EU) |
| Sector | Public |
| PI Contribution | Assistance in drafting the application and performance of comparative platelet activation assays. |
| Collaborator Contribution | Will allow for a multi-centre trial of new platelet activation assays |
| Impact | Outputs expected are publications resulting from the multi-centre testing of platelet activation kits. |
| Start Year | 2011 |
| Description | Myotonic Dystrophy |
| Organisation | GlaxoSmithKline (GSK) |
| Department | Discovery Partnerships with Academia |
| Country | Global |
| Sector | Private |
| PI Contribution | The proprietorial cell based assay will be explored by GSK to screen a coumpound librsry |
| Collaborator Contribution | Assistance with assay development |
| Impact | Although a lead candidate was identified GSK chose not to continue with the development programme. |
| Start Year | 2011 |
| Description | NPI |
| Organisation | University of Edinburgh |
| Department | Division of Pathology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Breast tissue microarray samples were provided from a cohort of Edinburgh patients. These were subject to immunohistochemical staining for a panel of biomarkers. |
| Collaborator Contribution | Nottingham Prognostics has performed all the histology and used its unique algorithms to assign breast cancer classes. |
| Impact | Once the data has been validated and any IP position confirmed; the results will be published. This is not a mulit-disciplinary collaboration. |
| Start Year | 2011 |
| Title | Heart rate monitor specifically designed for newborn babies requiring resuscitation at birth. |
| Description | "Approximately 70,000 newborns/yr in the UK (10% of births) require some form of resuscitation at birth. Many of these are premature or sick increasing their risk of morbidity and mortality. Newborns resuscitated but not admitted to the neonatal unit have an increased risk of poor cognitive function in later life. Heart rate (HR) is the best indicator of effective resuscitation and is currently assessed manually using a stethoscope. However, this is subject to human error, introduces delays, and may fail to detect a sudden deterioration. Hence, there is an urgent need for a HR monitor designed specifically for newborn delivery room resuscitation as current devices are unsuitable. This device aims to improve resuscitation practice, potentially improving outcomes and reducing time spent in intensive care. We have developed and patented a HR sensor specifically for this purpose. Preliminary work has demonstrated its use on babies in intensive care. DPFS funding is sought to further develop the technology for resuscitation in the delivery room and measure key performance parameters: namely accuracy, reliability and acquisition time. By placing this device in the hands of midwives and clinicians we aim to improve resuscitation in those infants at greatest risk of short and long term sequelae. Most recent work supported by DPFS Portfolio Award" |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Refinement. Clinical |
| Year Development Stage Completed | 2011 |
| Development Status | Under active development/distribution |
| Impact | TBC |
| Title | Platelet function test to monitor effects of drug therapy |
| Description | "Blood platelets contribute to thrombus formation in veins and arteries and thrombi are the main cause of clinical events such as heart attack and stroke. Drugs that reduce platelet function are used to reduce the incidence of such events; however they can also increase risk of bleeding. We have an established track record in developing and using tests of platelet function in diagnosis and for monitoring effects of drug therapy, and as new anti-platelet drugs come on the market, there is a growing demand for such tests. Current tests are timeconsuming, technically demanding or use expensive equipment that is not readily available. Recent progress in our laboratory is such that we now have a simplified test that, with further development, could be used in a wide range of settings. The aim of this application is a) to simplify the test further in collaboration with an industrial collaborator; and b) set up clinical trials to assess its value in a range of different clinical scenarios. Most recent work supported by DPFS Portfolio Award" |
| Type | Support Tool - For Medical Intervention |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2011 |
| Development Status | Actively seeking support |
| Impact | TBC |
| Title | The Greenbottle Pharmacy Project: Next Generation Wound Debridement Products |
| Description | "The Greenbottle Pharmacy Project sources wound care products from an organism, the greenbottle fly (Lucilla sericata), which is already used in the management of wounds. With Wellcome Trust, DSTL, EPSRC and TSB funding, we have identified a chymotrypsin from the secretions of L.sericata which completely digests eschar from human venous leg ulcers ex vivo and promotes alterations in fibroblast behaviour conducive to healing. This makes this particular chymotrypsin a prime candidate for development as a next generation wound debridement agent. Consequently, the enzyme has been cloned and expressed at a prototype level, and shown to mimic the effects of the whole organism in ex vivo debridement assays. Furthermore, we have incorporated the recombinant enzyme in a prototype formulation which clearly outperforms the leading competitor product Santyl. Confidence is high that the enzyme can now be developed through scale-up, formulation and toxicology to be ready for clinical evaluation within 2 years. The aim of the proposed project is to develop the product to a stage suitable for application ot wounds in patients. Most recent work supported by DPFS Portfolio Award" |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2011 |
| Development Status | On hold |
| Impact | TBC |
| Company Name | HeartLight Systems Limited |
| Description | HeartLight Systems was set up as a joint venture between the University of Nottingham and Tioga Ltd to develop neonatal monitoring systems based on novel detection sensors. |
| Year Established | 2014 |
| Impact | The company have recently received a TSB Biomedical Catalyst award to further develop the HeartLight monitors; the total project value is £1.74M. The Path to Market toolkit developed with support from EP/I500588/1 was critical in making the case for the Biomedical Catalyst Funding and also in securing initial pump priming investment for Heartlight Systems Ltd. |
| Company Name | Platelet Solutions Limited |
| Description | Platelet Solutions Ltd aims to use novel technology to measure platelet function simply and accurately in any clinical setting. A particular aim is to use the technology to optimize treatment of patients at-risk of heart attack or stroke with the effects of improving health care and reducing health costs. The technology will also be of diagnostic and therapeutic value in other diseases and in drug development programs. |
| Year Established | 2011 |
| Impact | The company has only been trading since 2011. Since January 2013 they have added two 0.5FTE posts and 1FTE |
| Website | http://www.plateletsolutions.co.uk/ |
| Company Name | Nottingham Prognostics Limited |
| Description | The business concerns the development and launch of a second-opinion website for breast cancer patients and their clinicians. The need for second opinions is increasing as treatment options multiply and patient awareness increases. The site will offer paid-for consultations which will include a personalised prognosis (initially) relating to survival. |
| Year Established | 2012 |
| Impact | No Scientific staff currently employed. |